Compare EFC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | MNKD |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2010 | 2004 |
| Metric | EFC | MNKD |
|---|---|---|
| Price | $12.81 | $5.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $14.54 | $10.08 |
| AVG Volume (30 Days) | 2.4M | ★ 4.2M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 12.14% | N/A |
| EPS Growth | 1.22 | ★ 23.47 |
| EPS | ★ 1.33 | 0.10 |
| Revenue | ★ $329,815,000.00 | $313,787,000.00 |
| Revenue This Year | N/A | $21.40 |
| Revenue Next Year | $8.81 | $25.03 |
| P/E Ratio | ★ $9.65 | $59.05 |
| Revenue Growth | 13.84 | ★ 17.43 |
| 52 Week Low | $11.12 | $3.38 |
| 52 Week High | $14.40 | $6.51 |
| Indicator | EFC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 27.36 | 51.71 |
| Support Level | $13.12 | $5.42 |
| Resistance Level | $13.50 | $5.94 |
| Average True Range (ATR) | 0.23 | 0.27 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 4.98 | 68.14 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.